The public science behind the 'Merck' Ebola vaccine

Merck will make very, very little money off this vaccine. The effort was never about the bottom line. It was about doing what needed to be done when few others could or would. Publicly funded Canadian research deserves praise for this work. But one can and should ask why those laboratories did not finish what they started. And it’s worth noting who did.

---

Also in Industry News